 The main objective of the study is the assessment of the overall graft rejection rate acute, chronic and subclinical between a treatment with ATG-Fresenius administered in addition to standard treatment consisting of CellCept or MyforticTAC and without corticosteroids and a treatment consisting of CellCept or MyforticTAC and corticosteroids during the first year after renal transplantation. 